Actively Recruiting
Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab
Led by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Updated on 2026-04-03
240
Participants Needed
2
Research Sites
369 weeks
Total Duration
On this page
Sponsors
I
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Lead Sponsor
B
BeOne Medicines
Collaborating Sponsor
AI-Summary
What this Trial Is About
The ReWoLuTe study (IKF091) is a prospective, multi-center, observational cohort study conducted in Germany and Austria to collect real-world data on the use of Tislelizumab-based therapies in patients with lung cancer. The study aims to evaluate the overall survival, treatment patterns, safety, and health-related quality of life of patients receiving Tislelizumab in everyday clinical practice.
CONDITIONS
Official Title
Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed resectable non-small cell lung cancer in stage II-IIIA with high risk of recurrence and eligible for curative surgery and Tislelizumab treatment in perioperative setting
- Or histologically confirmed locally advanced or metastatic lung cancer eligible for Tislelizumab treatment in approved indications, including:
- NSCLC squamous type, not candidate for surgery or platinum chemoradiation, no prior palliative treatment
- NSCLC non-squamous type with PD-L1 expression ≥50% without EGFR or ALK mutations, not candidate for surgery or platinum chemoradiation, no prior palliative treatment
- NSCLC squamous or non-squamous with prior platinum therapy; if EGFR or ALK positive, prior targeted therapy received
- Extensive-stage small cell lung cancer with no prior palliative treatment
- Decision for authorized Tislelizumab-based treatment made by treating physician before enrollment
- Patients who have received 1-2 cycles of therapy are eligible
- Patients switching from curative to palliative care before adjuvant treatment start are not excluded
You will not qualify if you...
- No signed informed consent provided
- Under 18 years of age at time of consent
- Unable to fully understand the implications of study participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Universitätsklinikum St. Pölten - Lilienfeld, Karl Landsteiner Privatuniversität für Gesundheitswissenschaften
Sankt Pölten, Lower Austria, Austria, 3100
Not Yet Recruiting
2
Krankenhaus Nordwest
Frankfurt am Main, Hesse, Germany, 60488
Actively Recruiting
Research Team
A
Akin Atmaca, PD Dr. med.
CONTACT
B
Bianca Zaepf
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here